Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Efficacy of heart failure treatments in diverse patient populations using induced pluripotent stem cell-derived cardiomyocytes
FY 2020-21
Summary
Heart failure plagues tens of millions of people annually, yet few treatment options are available to prevent a heart attack patient's condition from progressing to heart failure. Several currently approved drugs used for the medical management of heart failure have shown varying effects in patients. The extended time it takes to get patients on the right medication is detrimental to their health outcomes and contributes to a growing economic burden on the health care system. Clinical trials are often done on small populations without validating the drug efficacy in subpopulations such as in women, minorities, or the elderly, all of whom may react differently to the treatment. A new method of evaluating drug effectiveness in diverse patient populations is needed. This project will test the effectiveness of heart failure drugs in different demographic populations using patient-specific heart cells generated from blood samples. I will collect patient blood samples, reprogram them into cells with the potential to develop into many different cell types, otherwise known as stem cells, and then transform them into heart cells, called cardiomyocytes. Once cardiomyocytes are generated, we will induce a heart attack in these cells before treating them with currently available drugs. We will then analyze whether patient demographics, such as sex, race, and age, are predictors for these drugs' effectiveness since this is an important aspect of precision medicine. Additionally, this study will demonstrate the potential of patient-specific stem cell-derived cardiomyocytes for personalized drug-screening before prescribing heart failure drugs. Ultimately, this project seeks to improve patient health outcomes by prescribing them the most effective medication after a heart attack.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449589
Name
Zwaig Jeremy
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Efficacy of heart failure treatments in diverse patient populations using induced pluripotent stem cell-derived cardiomyocytes
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug Testing; Human Induced Pluripotent Stem Cells; Myocardial Infarction; Precision Medicine; Treatments For Heart Failure
Abstract
Heart failure plagues tens of millions of people annually, yet few treatment options are available to prevent a heart attack patient's condition from progressing to heart failure. Several currently approved drugs used for the medical management of heart failure have shown varying effects in patients. The extended time it takes to get patients on the right medication is detrimental to their health outcomes and contributes to a growing economic burden on the health care system. Clinical trials are often done on small populations without validating the drug efficacy in subpopulations such as in women, minorities, or the elderly, all of whom may react differently to the treatment. A new method of evaluating drug effectiveness in diverse patient populations is needed. This project will test the effectiveness of heart failure drugs in different demographic populations using patient-specific heart cells generated from blood samples. I will collect patient blood samples, reprogram them into cells with the potential to develop into many different cell types, otherwise known as stem cells, and then transform them into heart cells, called cardiomyocytes. Once cardiomyocytes are generated, we will induce a heart attack in these cells before treating them with currently available drugs. We will then analyze whether patient demographics, such as sex, race, and age, are predictors for these drugs' effectiveness since this is an important aspect of precision medicine. Additionally, this study will demonstrate the potential of patient-specific stem cell-derived cardiomyocytes for personalized drug-screening before prescribing heart failure drugs. Ultimately, this project seeks to improve patient health outcomes by prescribing them the most effective medication after a heart attack.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zwaig, Jeremy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~